Oxford BioDynamics (LON:OBD – Get Free Report) released its quarterly earnings data on Tuesday. The biotechnology company reported GBX (0.10) earnings per share for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative net margin of 1,018.54% and a negative return on equity of 316.67%. The firm had revenue of GBX 69 million during the quarter.
Oxford BioDynamics Stock Down 1.0%
LON:OBD opened at GBX 0.10 on Wednesday. Oxford BioDynamics has a fifty-two week low of GBX 0.08 and a fifty-two week high of GBX 0.78. The stock has a market capitalization of £4.25 million, a P/E ratio of -0.12 and a beta of 0.42. The company has a debt-to-equity ratio of 457.97, a quick ratio of 2.80 and a current ratio of 0.88. The company’s 50-day simple moving average is GBX 0.19 and its 200-day simple moving average is GBX 0.23.
About Oxford BioDynamics
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Recommended Stories
- Five stocks we like better than Oxford BioDynamics
- Burger King’s Turnaround Is Putting Restaurant Brands Back in Focus
- Short Squeeze Alert—Moderna Stock Surges on New Strategy
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
